“No question, we see that there’s a lot of heterogeneity in how penile cancer is managed across the United States,” says Philippe E. Spiess, MD, MS, FACS.
In this video, Philippe E. Spiess, MD, MS, FACS, discusses the key points of the penile cancer session being presented at the 2021 Society of Urologic Oncology Annual Meeting. Spiess is a genitourinary oncologist and assistant chief of surgical services at the Moffitt Cancer Center in Tampa, Florida.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.